← All trials
NCT05077215
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- Oct 14, 2021
- Last posted
- Oct 14, 2021
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Evergreen TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.